Dr. Haverfield is board-certified in clinical molecular genetics and has more than 12 years of experience in the medical genetics field. Prior to joining Invitae, Dr. Haverfield was the director of the whole exome sequencing program at GeneDx; before that, she was the assistant director of the genetic services laboratory at the University of Chicago. Dr. Haverfield earned her Master of Science in human biology and her doctorate in biological anthropology from the University of Oxford in Oxford, England. Read her full bio.

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Q: What are the products and/or services Invitae offers/develops to address this need? What makes Invitae unique?

A: Invitae offers genetic testing across all stages of life. Our offerings in diagnostic, reproductive health and proactive health information are backed by sound science and designed to deliver medically actionable information so that clinicians and their patients can use this information to inform healthcare decisions for the patient and their family.

Q: What is your role at Invitae and what excites you about your work?

A: As an American Board of Medical Genetics and Genomics (ABMGG)-certified clinical molecular geneticist, I work with a talented and experienced team at Invitae to sign out genetic testing results and provide consultations to referring clinicians and to develop new tests to address the needs in various clinical specialties. It is very exciting to be working in clinical genetics at Invitae where we approach our growth with a singular focus on how we can help more people benefit from understanding genetics and their health.

Q: When thinking about Invitae and the domain Invitae is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: We are seeing significant strides when it comes to the use of proactive testing. In a recent study in collaboration with Stanford University and Mayo Clinic, among others, more than 16% of individuals tested using our genetic health screen were found to have a clinically significant genetic change that would increase their risk of developing a serious hereditary cancer, cardiovascular or other medically important condition evaluated with this panel. These are conditions that, if detected early, may have effective medical surveillance, intervention and prevention measures.

Invitae’s work in this field has shown that significantly more people could benefit from this information than are currently tested, and for this reason, we are focused on answering this vast unmet need with high-quality, affordable genetic testing.

Q: What are the short-term challenges that Invitae and its peers are facing?

A: There is a lot of misunderstanding in the public about the differences between clinical-grade genetic testing and direct-to-consumer (DTC) tests, which is an important distinction. In the short term, it is essential that people understand that DTC test results should not be used to make medical decisions, and that they should seek a clinical-grade genetic test, like one from Invitae, to comprehensively understand their real risks of inherited disease.

Interview with Daniel Chen from IGM Biosciences

Q: Checkpoint inhibitors, particularly with PD-L1/PD-1 targeting agents, have benefited a broad range of patients with cancer. How will we improve on this?

A: It’s true that PD-L1/PD-1 inhibitors have led to durable responses in a subset of patients, and survival benefit in many of the patients treated- either as monotherapy or combination.

Read More

Call from PMWC 2019 Silicon Valley Program Committee – We Must Accelerate and Deliver on the Promise of Precision Medicine

Precision medicine advancements are real as demonstrated by the high volume of molecular, “precise” drugs on the market, which are based on extensive molecular and translational understanding of the specific drug targets.

Read More

#AI Play in Patient Diagnosis? How Can We Prepare the Next Generation to Make Sense of Enormous Amounts of Health-related Data?

What role should artificial intelligence play in patient diagnosis? How can we best prepare the next generation to make sense of enormous amounts of health-related data? These were just a few of the questions explored at the 15th Precision Medicine World Conference held at Duke University September 24-25, 2018.

Read More

Interview with Daniella Beller, Manager, Maccabi Research Institute Biobank

Q: What makes the Maccabi Research Institute biobank unique?

A: To explain the uniqueness of the Maccabi Biobank (named “Tipa” in Hebrew which means “drop” or “just a little”), first you must know a little about Maccabi.

Read More

Why We Need Public-Private Partnerships (PPP) To Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden.

Read More

Precision Medicine: A Decade of Improving the Standard of Care

In January, PMWC will host its 2019 Silicon Valley event, the largest Precision Medicine conference in the world with over 2,500 attendees gathering at the Santa Clara Convention Center. We are humbled and honored to have reached this stage of growth and are looking forward to continuing our work with key stakeholders and decision makers across the industry to ever strengthen this forum for exchange of critical and timely topics, to move the field of precision medicine forward and to improve the Standard of Care.

Read More

Interview with David Hong from Karius

Q: What need is Karius addressing?

A: Physicians often have difficulty pinpointing the exact pathogen that is causing disease. Conventional diagnostics like blood cultures or PCR can have poor sensitivity due to pretreatment with antibiotics, the breadth of potential pathogens present, and the requirement for invasive procedures to access deep-seated infections.

Read More

Interview with Charles Jaffe, MD, PhD from HL7

Q: What need is HL7 addressing?

A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.

Read More

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Read More

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).

Read More

Interview with William Hearl From Immunomic Therapeutics, Inc.

Q: What need is Immunomic Therapeutics, Inc. addressing?

A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.

Read More

Interview with Ralph Snyderman from Duke University

Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?

A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!
pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!